Differences in Fentanyl Requirements in Terminally Ill Cancer Patients

被引:1
作者
Watahabe, Aya [1 ,5 ]
Shimada, Naoki [1 ]
Ishiki, Hiroto [2 ]
Fujiwara, Noriko [1 ]
Nojima, Masanori [3 ]
Tojo, Arinobu [1 ,4 ]
机构
[1] Univ Tokyo, Res Hosp, Inst Med Sci, Dept Palliat Med, Tokyo, Japan
[2] Natl Canc Ctr, Dept Palliat Med, Tokyo, Japan
[3] Univ Tokyo, Inst Med Sci, Ctr Translat Res, Tokyo, Japan
[4] Univ Tokyo, Inst Med Sci, Dept Hematol Oncol, Tokyo, Japan
[5] Univ Tokyo, Res Hosp, Inst Med Sci, Dept Palliat Med, 4-6-1 Shirokanedai,Minato Ku, Tokyo 1088639, Japan
关键词
fentanyl patch requirement; pancreas cancer; palliative care; terminally ill cancer patients; RELEASE ORAL MORPHINE; TRANSDERMAL FENTANYL; PAIN; EFFICACY; GENDER; AGE;
D O I
10.1080/15360288.2022.2149667
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Cancer pain is a significant issue in terminally ill cancer patients (TICPs). The fentanyl patch (FP) is used extensively for treating cancer pain, but FP requirements vary between patients. We aimed to identify determinants of FP requirements in TICPs and propose effective pain relief using a FP. In a retrospective chart review, we investigated cancer patients admitted to our hospital from April 2012 to July 2015 and used FP until death. The time course of FP use in TICPs until death was examined. The primary endpoint was the final dose of FP use (FDFP). In total, 79 patients were included the analysis. FDFP was inversely correlated with age (R= -0.262, p = 0.20; Spearman test). FDFP tended to be higher in males than in females and was significantly higher in patients with pancreatic cancer than in patients without pancreatic cancer (p = 0.017; Welch's test). FP adjustments were more frequent in the last 60 days of life in patients with pancreatic cancer than in patients with other malignancies (P for interaction = 0.002; mixed effect model). In conclusion, younger age, and pancreatic cancer were associated with higher FP requirements in TICPs. TICPs with pancreatic cancer required more frequent FP adjustment near death.
引用
收藏
页码:26 / 33
页数:8
相关论文
共 20 条
[1]   Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life [J].
Ahmedzai, S ;
Brooks, D .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1997, 13 (05) :254-261
[2]  
[Anonymous], 2018, WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents
[3]   Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain [J].
Clark, AJ ;
Ahmedzai, SH ;
Allan, LG ;
Camacho, F ;
Horbay, GLA ;
Richarz, U ;
Simpson, K .
CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (09) :1419-1428
[4]   Transdermal fentanyl for cancer pain [J].
Hadley, Gina ;
Derry, Sheena ;
Moore, R. Andrew ;
Wiffen, Philip J. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (10)
[5]   The terminal cancer patient: Effects of age, gender, and primary tumor site on opioid dose [J].
Hall, S ;
Gallagher, RM ;
Gracely, E ;
Knowlton, C ;
Wescules, D .
PAIN MEDICINE, 2003, 4 (02) :125-134
[6]  
Hameed Mariam, 2010, Cancers (Basel), V3, P43, DOI 10.3390/cancers3010043
[7]  
Higginson Irene J., 1993, Palliative Medicine, V7, P219, DOI 10.1177/026921639300700309
[8]   Relationship between the plasma fentanyl and serum 4β-hydroxycholesterol based on CYP3A5 genotype and gender in patients with cancer pain [J].
Ishida, Takuya ;
Naito, Takafumi ;
Sato, Hikaru ;
Kawakami, Junichi .
DRUG METABOLISM AND PHARMACOKINETICS, 2016, 31 (03) :242-248
[9]   A new once-a-day fentanyl citrate patch (FentosA® Tape) could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch [J].
Koike, Kazuhiko ;
Terui, Takeshi ;
Nagasako, Tomokazu ;
Horiuchi, Iori ;
Machino, Takayuki ;
Kusakabe, Toshiro ;
Hirayama, Yasuo ;
Mihara, Hiroyoshi ;
Yamakage, Michiaki ;
Kato, Junji ;
Nishisato, Takuji ;
Ishitani, Kunihiko .
SUPPORTIVE CARE IN CANCER, 2016, 24 (03) :1053-1059
[10]   Presenting symptoms of cancer and stage at diagnosis: evidence from a cross-sectional, population-based study [J].
Koo, Minjoung Monica ;
Swann, Ruth ;
McPhail, Sean ;
Abel, Gary A. ;
Elliss-Brookes, Lucy ;
Rubin, Greg P. ;
Lyratzopoulos, Georgios .
LANCET ONCOLOGY, 2020, 21 (01) :73-79